Bambancin Lambda ya ja hankali a matsayin wata sabuwar barazana a cikin ci gaban cutar ta COVID-19
Bambancin Lambda na coronavirus, wanda aka fara gano shi a cikin Peru a watan Disamba, na iya komawa baya, amma kuma yana da damar haifar da mummunar cuta idan ba a daina ba. An sami kararraki a Texas da South Carolina, kuma a cikin kashi 81% na lamuran da aka samu a Peru.
Bambancin Lambda yana da maye gurbi da ke tsayayya da allurar rigakafi.

Sauye -sauye guda biyu a cikin bambancin Lambda - T76I da L452Q - sun sa ya fi kamuwa da cuta fiye da bambancin COVID da ya ratsa duniya a 2020

Ƙarshen binciken ya yi daidai da binciken da wata ƙungiya a Chile ta gano cewa bambance -bambancen na iya kuma gujewa ƙwayoyin rigakafi, in ji rahoton kamuwa da cuta na Chile.

Har yanzu ba a sake duba wannan rahoton ta takwarorina ba.

Bambancin COVID-19 wanda ke tabbatar da tsayayya da alluran rigakafi yana kiyaye kwararrun likitocin, jami'an kiwon lafiyar jama'a, da ƙwararrun masu kula da lafiya a fagen fama da cutar ta COVID-19 cikin dare.

Menene bambancin Lambda bisa ga binciken daga Chile?

Tarihi Sabuwar layin SARS-CoV-2 C.37 an bayyana shi kwanan nan a matsayin bambancin sha'awa ta WHO (Bambancin Lambda) dangane da yawan yaɗuwarta a ƙasashen Kudancin Amurka da kasancewar manyan canje-canje a cikin furotin. Ba a san tasirin irin wannan maye gurbi a cikin kamuwa da cuta da kubuta daga garkuwar jiki ba.

Hanyar Mun yi gwajin wariyar ƙwayar cuta ta pseudotyped kuma mun ƙaddara tasirin bambancin Lambda akan kamuwa da cuta da tserewa daga rigakafi ta amfani da samfuran plasma daga ma'aikatan kiwon lafiya (HCW) daga cibiyoyi biyu a Santiago, Chile waɗanda suka karɓi tsarin allurai biyu na allurar rigakafin cutar CoronaVac.

results:
Mun lura da karuwar kamuwa da cuta wanda furotin na Lambda ya haɓaka wanda har ma ya fi na D614G (jinsi B) ko bambance -bambancen Alpha da Gamma. Idan aka kwatanta da nau'in daji (jinsi A), an rage tsaka-tsakin ta 3.05-ninki don bambancin Lambda yayin da ya kasance 2.33 don bambancin Gamma da 2.03-ninka don bambancin Alpha.

karshe Sakamakonmu yana nuna cewa maye gurbi da ke cikin furotin mai ban sha'awa na bambancin Lambda yana ba da ƙarin kamuwa da cuta da tserewa daga ƙwayoyin cuta da CoronaVac ya haifar. Waɗannan bayanan suna ƙarfafa ra'ayin cewa babban kamfen na allurar rigakafin cutar a cikin ƙasashe masu babban yaɗuwar SARS-CoV-2 dole ne ya kasance tare da tsananin sa ido na ƙwayoyin cuta wanda ke ba da damar gano sabbin keɓewa waɗanda ke ɗauke da maye gurbi da kuma nazarin rigakafin rigakafi da nufin tantance tasirin waɗannan maye gurbi a cikin tserewa na rigakafi da alluran rigakafin.

Bayyanar bambance-bambancen SARS-CoV-2 na damuwa da bambance-bambancen sha'awa sun kasance alamar cutar ta COVID-19 yayin 2021.

Sabuwar layin SARS-CoV-2 C.37 da aka sanya kwanan nan WHO ta baiyana shi azaman bambancin sha'awa a ranar 14 ga Yuni^th kuma an lasafta shi azaman bambancin Lambda. An ba da rahoton kasancewar wannan sabon nau'in a cikin ƙasashe sama da 20 kamar na Yuni 2021 tare da mafi yawan jerin abubuwan da ke samuwa daga ƙasashen Kudancin Amurka, musamman daga Chile, Peru, Ecuador da Argentina.⁵. Wannan sabon bambance-bambancen na sha'awa yana nuna kasancewar kasancewar juyawa mai jujjuyawa a cikin nau'in ORF1a (Δ3675-3677) wanda aka riga aka bayyana a cikin bambance-bambancen Beta da Gamma na damuwa da maye gurbi Δ246-252, G75V, T76I, L452Q, F490S, T859N a cikin gina jiki mai gina jiki⁶. Ba a san tasirin waɗannan maye gurbi a kan kamuwa da cuta da tserewa zuwa kawar da ƙwayoyin rigakafi ba.

A halin yanzu kasar Chile tana gudanar da wani gagarumin shirin allurar rigakafi. Dangane da bayanan jama'a daga Ma'aikatar Lafiya ta Chile har zuwa ranar 27 ga Yuni^th 2021, 65.6% na yawan mutanen da aka yi niyya (shekaru 18 da tsufa) sun sami cikakkiyar tsarin rigakafin⁷. Mafi yawan (78.2%) na cikakken allurar rigakafin sun karɓi tsarin allurai biyu na rigakafin ƙwayar cutar CoronaVac, wanda a baya aka ba da rahoton cewa yana haifar da kawar da ƙwayoyin cuta amma a ƙananan titers idan aka kwatanta da plasma ko sera daga mutane masu haɗaka.

Anan, mun yi amfani da gwajin tsattsarkar ƙwayar cuta da aka bayyana a baya¹² don tantance tasirin bambance -bambancen Lambda akan martanin rigakafin ƙwayoyin cuta wanda allurar rigakafin cutar CoronaVac ta haifar. Bayanai na mu sun nuna cewa maye gurbi da ke cikin furotin mai banbanci na bambance -bambancen Lambda yana ba da ƙarin kamuwa da cuta da tserewa don kawar da ƙwayoyin rigakafi da allurar rigakafin cutar CoronaVac.

Hanyar

Ma'aikatan kiwon lafiya daga shafuka biyu a Santiago, Chile an gayyace su don shiga. Masu ba da agaji sun karɓi tsarin allurai na CoronaVac, kowane kashi ana gudanar da shi kwanaki 28 baya ga shirin allurar rigakafin na Chile. An tattara samfuran Plasma tsakanin watan Mayu zuwa Yuni 2021. Duk mahalarta sun sanya hannu kan yardar sanarwa kafin a aiwatar da duk wani tsarin binciken.

ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:

This new variant of interest is characterized by the presence of a convergent deletion in the ORF1a gene (Δ3675-3677) already described in the Beta and Gamma variants of concern and mutations Δ246-252, G75V, T76I, L452Q, F490S, T859N in the spike protein6.
Methods We performed a pseudotyped virus neutralization assay and determined the impact of the Lambda variant on infectivity and immune escape using plasma samples from healthcare workers (HCW) from two centers in Santiago, Chile who received the two-doses scheme of the inactivated virus vaccine CoronaVac.
These data reinforce the idea that massive vaccination campaigns in countries with high SARS-CoV-2 circulation must be accompanied by strict genomic surveillance allowing the identification of new isolates carrying spike mutations and immunology studies aimed to determine the impact of these mutations in immune escape and vaccines breakthrough.